HC Wainwright Brokers Increase Earnings Estimates for NTLA

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at HC Wainwright increased their FY2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Monday, November 10th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($3.88) per share for the year, up from their prior estimate of ($4.38). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q4 2025 earnings at ($0.89) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.66) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.10. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The company had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.12 million. During the same quarter last year, the company posted ($1.34) EPS. The firm’s revenue was up 51.6% compared to the same quarter last year.

NTLA has been the topic of a number of other research reports. JMP Securities reduced their price target on Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating on the stock in a research report on Tuesday, October 28th. Truist Financial reaffirmed a “buy” rating and issued a $14.00 target price (down previously from $25.00) on shares of Intellia Therapeutics in a report on Monday. JPMorgan Chase & Co. reiterated an “underweight” rating and set a $5.00 price target (down previously from $12.00) on shares of Intellia Therapeutics in a report on Friday, November 7th. Sanford C. Bernstein set a $14.50 target price on Intellia Therapeutics in a research note on Tuesday, October 28th. Finally, Royal Bank Of Canada lowered their target price on shares of Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating for the company in a report on Friday, November 7th. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $18.25.

Intellia Therapeutics Trading Up 4.6%

Shares of NASDAQ NTLA opened at $10.18 on Wednesday. The stock has a market cap of $1.18 billion, a P/E ratio of -2.38 and a beta of 2.44. The business’s fifty day simple moving average is $17.13 and its 200-day simple moving average is $12.56. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.25.

Institutional Trading of Intellia Therapeutics

Several large investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. raised its stake in shares of Intellia Therapeutics by 51.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock worth $140,000 after buying an additional 6,722 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Intellia Therapeutics by 9.7% in the first quarter. Envestnet Asset Management Inc. now owns 73,150 shares of the company’s stock valued at $520,000 after purchasing an additional 6,496 shares in the last quarter. CWM LLC increased its stake in shares of Intellia Therapeutics by 904.2% during the 1st quarter. CWM LLC now owns 14,912 shares of the company’s stock worth $106,000 after purchasing an additional 13,427 shares in the last quarter. Grandfield & Dodd LLC raised its position in shares of Intellia Therapeutics by 56.4% during the 1st quarter. Grandfield & Dodd LLC now owns 48,645 shares of the company’s stock worth $346,000 after purchasing an additional 17,550 shares during the last quarter. Finally, LMG Wealth Partners LLC lifted its stake in Intellia Therapeutics by 28.4% in the 1st quarter. LMG Wealth Partners LLC now owns 14,285 shares of the company’s stock valued at $102,000 after buying an additional 3,157 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Michael P. Dube sold 1,871 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the sale, the chief accounting officer owned 55,266 shares in the company, valued at approximately $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William J. Chase acquired 100,000 shares of the business’s stock in a transaction on Wednesday, August 20th. The shares were purchased at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the transaction, the director owned 134,693 shares in the company, valued at $1,350,970.79. The trade was a 288.24% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.10% of the stock is owned by corporate insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.